Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 11/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 10/20 | 0.47 |
| ▸ | GAS6 | Q14393 | 8/20 | 0.47 |
| ▸ | FLT3 | P36888 | 7/20 | 0.47 |
| ▸ | AXL | P30530 | 4/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26930786 | 1.00 | MERTK (0.47) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16435468 | 1.00 | MERTK (0.47) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL28533353 | 0.90 | KMT2A (0.55) | MERTKAXLMAPK8MAPK9KMT2A | |
| SCHEMBL20354306 | 0.90 | KMT2A (0.51) | AXLMAPK8MAPK9KMT2A | |
| SCHEMBL23452672 | 0.88 | NR2F2 (0.53) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL30736374 | 0.88 | NR2F2 (0.53) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL20329838 | 0.88 | NR2F2 (0.53) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL20299341 | 0.88 | NR2F2 (0.53) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL14657977 | 0.85 | MAPK8 (0.55) | MAPK8MAPK9KMT2A | |
| SCHEMBL30873290 | 0.85 | MAPK8 (0.55) | MAPK8MAPK9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019006548-A1 | FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS MER TYROSINE KINASE (MERTK) INHIBITORS AND USES THEREOF | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-10 | — | — | WO | disclosed |
| US-9771330-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-09-26 | — | — | US | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | MERTK, FLT3, TK1 | MERTK 1/4885TYRO3 41/4885GAS6 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.